| Griffin, Paul |
| Terminated | 3 | 409 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 09/24 | | |
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine |
|
|
| Not yet recruiting | 3 | 7950 | RoW | CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD | Novavax | COVID-19 | 03/25 | 04/25 | | |
NCT05734040: Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. |
|
|
| Completed | 2 | 478 | RoW | OVX836 480µg, Fluarix Tetra, Afluria Quad, Placebo | Osivax, Novotech (Australia) Pty Limited, Mater Misericordiae Limited | Influenza | 08/23 | 01/24 | | |
NCT04495933: A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults |
|
|
| Completed | 1 | 216 | RoW | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg, Placebo | The University of Queensland, Syneos Health, Coalition for Epidemic Preparedness Innovations | SARS-CoV2, Covid19 | 04/24 | 04/24 | | |
NCT05116865: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers |
|
|
| Completed | 1 | 52 | RoW | HH-120 Dose 1, HH-120, HH-120 Dose 2, HH-120 Dose 3, Placebo | Huahui Health | COVID-19 Respiratory Infection | 05/22 | 08/22 | | |
| McLendon, Kristi |
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine |
|
|
| Not yet recruiting | 3 | 7950 | RoW | CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD | Novavax | COVID-19 | 03/25 | 04/25 | | |
| Completed | 1 | 23 | RoW | EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg), Epinephrine (4mg) | De Motu Cordis, Novotech (Australia) Pty Limited | Anaphylactic Reaction | 06/22 | 06/22 | | |
NCT05340790: First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories |
|
|
| Recruiting | 1 | 50 | RoW | Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, AMP PL-18, Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, Placebo PL-18 | Protelight Pharmaceuticals Australia PTY LTD | Colpomycosis, Bacterial Vaginosis, Mixede Vaginitis | 12/23 | 03/24 | | |
NCT05775887: A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS. |
|
|
| Completed | 1 | 70 | RoW | UQSC2 Vaccine, NVX-CoV2373 vaccine | The University of Queensland, Coalition for Epidemic Preparedness Innovations | COVID-19 | 12/23 | 12/23 | | |
NCT05805618: Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 60 | NA | Recombinant Norovirus Hexavalent Vaccine, KH002, Matching Placebo | Syneos Health, Chengdu Kanghua Biological products Co., Ltd. | Gastroenteritis | 11/24 | 11/24 | | |
NCT05799651: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults |
|
|
| Active, not recruiting | 1 | 36 | RoW | Glycovax-002 | Glycovax Pharma Inc., Government of Canada, JSS Medical Research Inc., Avance Clinical Pty Ltd., Seppic | SARS-CoV-2 | 06/24 | 12/24 | | |
NCT05053334: Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair |
|
|
| Completed | 1 | 165 | RoW | Omalizumab Prefilled Syringe | Syneos Health, CuraTeQ Biologics Private Ltd. | Healthy Volunteers | 11/23 | 11/23 | | |
| Recruiting | 1 | 32 | RoW | Adamgammadex Sodium, Aom0319, 0.9% Sodium Chloride Injection, Placebo | Amckaus PTY LTD. | Healthy Volunteers | 12/23 | 06/24 | | |
NCT06019065: A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects |
|
|
| Completed | 1 | 64 | RoW | AJA001, Placebo | AJNA Australia Pty Ltd | Healthy Volunteers | 03/24 | 05/24 | | |
| Recruiting | 1 | 56 | RoW | ZT002, Placebo | QL Biopharmaceutical Australia Pty Ltd, Novotech (Australia) Pty Limited, Beijing QL Biopharmaceutical Co.,Ltd | Type 2 Diabetes Mellitus | 12/23 | 04/24 | | |
NCT06125691: Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults |
|
|
| Active, not recruiting | 1 | 135 | RoW | ARCT-2138, Self-Amplifying RNA seasonal Influenza vaccine, Licensed Quadrivalent Vaccine for younger adults, Influenza vaccine, surface antigen, inactivated, prepared in cell cultures, Licensed Quadrivalent Vaccine for older adults, Influenza vaccine, surface antigen, inactivated, adjuvanted | Arcturus Therapeutics, Inc., Seqirus, Novotech (Australia) Pty Limited | Influenza, Human | 09/24 | 01/25 | | |
NCT05905068: Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects |
|
|
| Completed | 1 | 32 | RoW | RN0191 INJECTION | Ikaria Bioscience Pty Ltd | To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities | 02/24 | 05/24 | | |
NCT06028347: Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults |
|
|
| Active, not recruiting | 1 | 96 | RoW | sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3, Placebo | Seqirus | Influenza, Human | 10/24 | 10/24 | | |
NCT05896969: Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol |
|
|
| Completed | 1 | 41 | RoW | SNK-396 - SAD cohort, SNK-396 - MAD Cohort | Syneos Health, SynerK Pharmatech (Suzhou) Limited | Elevated Low-Density Lipoprotein Cholesterol | 02/24 | 02/24 | | |
| Lendon, Kristi Mc |
NCT05863442: Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants |
|
|
| Recruiting | 1 | 120 | RoW | Soliris 300 MG in 30 ML Injection, TUR03 300 MG in 30 ML Injection | Turgut Ardika PTY LTD | Healthy | 07/24 | 10/24 | | |
| Officer, Complaints |
NCT05863442: Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants |
|
|
| Recruiting | 1 | 120 | RoW | Soliris 300 MG in 30 ML Injection, TUR03 300 MG in 30 ML Injection | Turgut Ardika PTY LTD | Healthy | 07/24 | 10/24 | | |
